rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A 66-year-old man was diagnosed with relapsed stage IV non-small cell lung cancer with an EGFR mutation in exon 21 (L858R) 2 years after stereotactic body radiotherapy.
|
31486987 |
2019 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A 66-year-old man was diagnosed with relapsed stage IV non-small cell lung cancer with an EGFR mutation in exon 21 (L858R) 2 years after stereotactic body radiotherapy.
|
31486987 |
2019 |
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A 66-year-old man was diagnosed with relapsed stage IV non-small cell lung cancer with an EGFR mutation in exon 21 (L858R) 2 years after stereotactic body radiotherapy.
|
31486987 |
2019 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A decision model was developed to evaluate the budget impact of increases in afatinib share for the first-line treatment of patients with metastatic NSCLC with EGFR del19 or L858R substitution mutations over a 5-year time horizon.
|
29799327 |
2018 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A decision model was developed to evaluate the budget impact of increases in afatinib share for the first-line treatment of patients with metastatic NSCLC with EGFR del19 or L858R substitution mutations over a 5-year time horizon.
|
29799327 |
2018 |
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A decision model was developed to evaluate the budget impact of increases in afatinib share for the first-line treatment of patients with metastatic NSCLC with EGFR del19 or L858R substitution mutations over a 5-year time horizon.
|
29799327 |
2018 |
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
BRAF-MEK combination therapy (dabrafenib plus trametinib) demonstrated tolerability and efficacy in a recent phase II clinical trial and was approved by the European Medicines Agency and United States Food and Drug Administration for patients with stage IV NSCLC harboring BRAF V600E mutation.
|
29595366 |
2019 |
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
BRAF-MEK combination therapy (dabrafenib plus trametinib) demonstrated tolerability and efficacy in a recent phase II clinical trial and was approved by the European Medicines Agency and United States Food and Drug Administration for patients with stage IV NSCLC harboring BRAF V600E mutation.
|
29595366 |
2019 |
rs1051730
|
|
|
0.010 |
GeneticVariation |
BEFREE |
CHRNA3 (rs1051730) genotyping can improve customized chemotherapy based on tumor assessment of ERCC1 mRNA in stage IV NSCLC with PS 0.
|
19733931 |
2010 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Conclusion Use of gefitinib for the first-line therapy of metastatic nonsmall cell lung cancer with epidermal growth factor receptor exon 19 deletions (residues 747-750) or exon 21 substitution mutation (L858R) is well-documented and supported.
|
26911477 |
2017 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Conclusion Use of gefitinib for the first-line therapy of metastatic nonsmall cell lung cancer with epidermal growth factor receptor exon 19 deletions (residues 747-750) or exon 21 substitution mutation (L858R) is well-documented and supported.
|
26911477 |
2017 |
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Conclusion Use of gefitinib for the first-line therapy of metastatic nonsmall cell lung cancer with epidermal growth factor receptor exon 19 deletions (residues 747-750) or exon 21 substitution mutation (L858R) is well-documented and supported.
|
26911477 |
2017 |
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
|
27283860 |
2016 |
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
|
27283860 |
2016 |
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Due to the rarity of BRAF V600E mutation, no randomized study has compared the combination targeted therapy dabrafenib + trametinib with other second-line treatments for advanced or metastatic non-small-cell lung cancer (NSCLC).
|
29949047 |
2018 |
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Due to the rarity of BRAF V600E mutation, no randomized study has compared the combination targeted therapy dabrafenib + trametinib with other second-line treatments for advanced or metastatic non-small-cell lung cancer (NSCLC).
|
29949047 |
2018 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Eligible patients were aged 18 years or older (20 years or older in Japan and Taiwan) at the time of study entry, had stage IV NSCLC, with an EGFR exon 19 deletion (ex19del) or exon 21 substitution (Leu858Arg) mutation, an Eastern Cooperative Oncology Group performance status of 0 or 1, and no CNS metastases.
|
31591063 |
2019 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Eligible patients were aged 18 years or older (20 years or older in Japan and Taiwan) at the time of study entry, had stage IV NSCLC, with an EGFR exon 19 deletion (ex19del) or exon 21 substitution (Leu858Arg) mutation, an Eastern Cooperative Oncology Group performance status of 0 or 1, and no CNS metastases.
|
31591063 |
2019 |
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Eligible patients were aged 18 years or older (20 years or older in Japan and Taiwan) at the time of study entry, had stage IV NSCLC, with an EGFR exon 19 deletion (ex19del) or exon 21 substitution (Leu858Arg) mutation, an Eastern Cooperative Oncology Group performance status of 0 or 1, and no CNS metastases.
|
31591063 |
2019 |
rs121434569
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291).
|
28367058 |
2017 |
rs121434569
|
|
|
0.070 |
GeneticVariation |
BEFREE |
FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.
|
29242281 |
2018 |
rs121913236
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Herein we identified a KRAS Q22K mutation and frameshift mutations in the genes encoding serine/threonine kinase 11 (STK11) and ataxia telangiectasia mutated serine/threonine kinase (ATM) by next-generation sequencing in a patient with ALK rearrangement-positive oligo-metastatic NSCLC, whose disease progressed while on two ALK-targeted therapies.
|
25964588 |
2015 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In September 2018, dacomitinib received its first global approval, in the USA, for use in the first-line treatment of patients with metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.
|
30506139 |
2018 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In September 2018, dacomitinib received its first global approval, in the USA, for use in the first-line treatment of patients with metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.
|
30506139 |
2018 |
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In September 2018, dacomitinib received its first global approval, in the USA, for use in the first-line treatment of patients with metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.
|
30506139 |
2018 |